AlphAIAlphAI — Financial news for AI agents
investing.comNOV 31 min read$TARS

Tarsus earnings missed by $12.93, revenue topped estimates

Tarsus (NASDAQ: TARS) reported Q3 EPS of -$14.40, missing estimates by $12.93, but revenue of $194.5M topped expectations. The stock is up 12.12% over 3 months and 1.59% over 12 months. Analysts revised EPS estimates 1 positive and 2 negative times in the last 90 days.

Original reporting
investing.com
Published Nov 3, 2026, 10:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TARS
Bearish
high confidence
Mentioned
$TARS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TARSBearishMed
01

Why it matters

The earnings miss is the primary new information, likely prompting a short-term price decline.

02

Market read

Earnings miss for a listed micro-cap; relevant for short-term traders.

03

What to watch

Potential one-time charges behind the EPS miss not detailed in the brief.

Relevance 7/10Novelty 8/10Timing: post-market reaction

Background

Tarsus (NASDAQ:TARS) is a small-cap company; the article provides its latest quarterly earnings figures.

Company-level read

Ticker impact

$TARSBearishHigh confidence
Context

Tarsus reported Q3 EPS of $-14.40, missing estimates by $12.93 and revenue of $194.5M versus $183.95M consensus.

Expected impact

likely pressure as the market prices in the earnings miss

Evidence & confidence

The sizable EPS miss outweighs the modest revenue beat, prompting traders to downgrade expectations.

Market effects

Sector

May weigh on other small-cap biotech/tech firms reporting earnings.

Regional

Limited to US-listed micro-cap segment.

Global

Low global impact.

Counterpoint

What could challenge this read

Revenue beat could suggest upside if the market overreacts to the EPS miss.

Key entities

  • company
    Tarsus

    NASDAQ-listed micro-cap reporting Q3 results.

Read at source← All news

StoryTarsus posts acquisition-driven Q3 loss and raises XDEMVY outlook

Also covered by

2 outlets

Related articles

NOV 4
$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.

finance.yahoo.com2 min
NOV 3
$TARSMed

Tarsus Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales si

SEC EDGAR 8-K2 min
SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min